Johnson & Johnson’s medical device revenues rebounded faster in the third quarter than the company previously anticipated, as procedure volumes continue to recover from the initial shock of the pandemic, especially in the US and China.
“We exceeded our expectations as the market recovery was even stronger than anticipated, as hospitals and surgeons continued to work through the pent-up demand resulting from restrictions on procedures earlier...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?